Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Biopharma Corporation announced that they were notified via verbal communication from the US FDA that the AB-101 Investigational New Drug (IND) application has been placed on clinical hold.